Phase II study of spirohydantoin mustard for the treatment of recurrent malignant gliomas.
D000328:Adult; D001932:Brain Neoplasms / Q000188:drug therapy*; D003953:Diagnosis-Related Groups; D004341:Drug Evaluation; D005260:Female; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D006827:Hydantoins / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D010830:Physostigmine / Q000627:therapeutic use
D006827:Hydantoins; D009588:Nitrogen Mustard Compounds; D010830:Physostigmine; C015511:spiromustine